Navigating Treatment Decision-Making in Newly Diagnosed Glioblastoma
Multidisciplinary experts discuss real-world decision-making in newly diagnosed glioblastoma (GBM), incorporating patient preferences into treatment planning, managing uncertainty in suspected pseudoprogression, and interpreting the role of MGMT promoter methylation—highlighting practical considerations that shape care in everyday practice.
Round 1
Patient Factors and Treatment Decision-Making
The debate begins with a younger, high-functioning patient with favorable biology. The panelists explore how patient characteristics and preferences influence treatment planning, with discussion focused on feasibility, adherence, and the role of shared decision-making.
Round 2
Managing Suspected Pseudoprogression
The discussion turns to early post-treatment imaging changes, with panelists debating how to approach management when progression is suspected but not confirmed. Key considerations include clinical stability, interpretation of imaging, and balancing the risks of acting too early versus waiting for greater clarity.
Round 3
Biomarker-Guided Decision-Making
In the third round, panelists examine how MGMT promoter methylation status informs treatment decisions, particularly in patients with unmethylated disease. The discussion focuses on how biomarker data is weighed alongside clinical factors to guide overall strategy.
© 2026 HMP Global. All Rights Reserved.
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
